Oslo, Norway, 10 July 2017

Three of the board members of Nordic Nanovector ASA (the "Company") (OSE: NANO),
Gisela Schwab, Joanna Horobin and Jean-Pierre Bizzari, have resolved to settle a
total number of 13,259 RSUs that were issued pursuant to an authorisation
granted to the board of directors at the annual general meeting in 2016. Each
RSU gives the right to subscribe for one share in the Company at a subscription
price of NOK 0.20. The board members were granted the RSUs after the annual
general meeting in 2016 after having elected to receive all or part of their
remuneration for the period from the annual general meeting in 2016 to the
annual general meeting in 2017 in RSUs.

The Board of Directors of the Company has, to fulfil the Company's obligations
under the RSU agreements, resolved to issue 13,259 new shares at a subscription
price of NOK 0.20 per share giving a total subscription price of NOK 2,651.80.
The Company's share capital will through the issuance of the new shares, bee
increased by NOK 2,651.80. Subsequent to the issuance of the new shares, the
Company's share capital will be NOK 9,808,880.40 divided into 49,044,402 shares,
each with a nominal of NOK 0.20.

Gisela Schwab, Joanna Horobin and Jean-Pierre Bizzari have subscribed for 7,054
new shares, 2,678 new shares and 3,527 new shares respectively at a subscription
price of NOK 0.20 per share. The three board members will following issuance of
the new shares, have the following holding of shares and RSUs in the Company:

+-------------------+--------------------+----------------------+
|Name               |Total number of RSUs|Total number of shares|
+-------------------+--------------------+----------------------+
|Gisela Schwab      |2,946               |7,054                 |
+-------------------+--------------------+----------------------+
|Joanna Horobin     |2,107               |2,678                 |
+-------------------+--------------------+----------------------+
|Jean-Pierre Bizzari|982                 |3,527                 |
+-------------------+--------------------+----------------------+

For further information, please contact:
Tone Kvåle, Chief Financial Officer
Phone: +47 91 51 95 76
E-mail: tkvale@nordicnanovector.com

About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
company aspires to become a leader in the development of targeted therapies for
haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37
-targeting Antibody-Radionuclide-Conjugate (ARC) designed to advance the
treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial
unmet medical need, representing a growing market forecast to be worth nearly
USD 20 billion by 2024.
The Company aims to rapidly develop Betalutin®, alone and in combination with
other therapies, for the treatment of major types of NHL, targeting first
regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019.
Nordic Nanovector intends to retain marketing rights and to actively participate
in the commercialisation of Betalutin® in core markets.

The Company is also advancing a pipeline of ARCs and other immunotherapies for
multiple cancer indications.
Further information about the Company can be found at www.nordicnanovector.com

